News

The antiviral treatment remdesivir accelerated recovery time among hospitalized participants with advanced COVID-19 compared to participants who received placebo containing inactive ingredients, according to results of a clinical trial published May 22 in the New England Journal of Medicine.  

Is a single dose of a human papillomavirus (HPV) vaccine sufficient to induce an immune response capable of preventing HPV infection and cervical cancer? That is an area of focus of the Frederick National Laboratory’s HPV Serology Laboratory, this time with a new collaboration with the London School of Hygiene & Tropical Medicine School to investigate immune responses to a single dose of the HPV vaccine in girls in Tanzania.  

As COVID-19 spread around the U.S., health care providers needed guidelines to treat patients—and they needed them fast.

The solution? A website that would house data- and expert-backed clinical treatment guidelines devised by a panel of U.S. physicians, statisticians, and other experts from the National Institutes of Health (NIH), universities, and health care organizations.

The Frederick National Laboratory led a collaborative project to build one, finishing in just two weeks.

The Pamoja Tulinde Maisha (PALM, Kiswahili for “together save lives”) trial, a large Ebola research effort supported by the Frederick National Laboratory, has received the David Sackett Trial of the Year Award for 2019.

Lindsay Dutko in the Molecular Characterization Laboratory's histology group.

Tissue obtained from tumors during an autopsy conducted shortly after a cancer patient’s death provides unique insights into how the tumors evolved, spread and resisted treatment. The Frederick National Laboratory’s Molecular Characterization Laboratory reports on results of a study on preclinical models established from “rapid autopsy” tumors during the 2020 American Society for Clinical Oncology Virtual Scientific Program, May 29-31.

HPV Serology Laboratory team

In its urgent efforts to confront the novel coronavirus, the U.S. Food and Drug Administration (FDA) has tapped the Frederick National Laboratory for Cancer Research (FNL) to scientifically inform its decision-making on potential approval of blood tests for the presence of antibodies to SARS-CoV-2.

The HPV Serology Laboratory team led by Dr. Ligia Pinto.

Histopathology slide showing staining for the four target cell types in MoNuSAC

Three employees from Frederick National Laboratory’s Imaging and Visualization Group recently claimed a top spot of a computing and artificial intelligence challenge that attracted 170 competing groups from around the world.

Trent Balius

A scientific paper on a member of the RAS family of oncogenes published last summer so intrigued Frederick National Laboratory computational scientist Trent Balius that he and his and colleagues performed a follow-up study, shedding more light on the topic.

Cancer is beginning to eclipse infectious disease as a major cause of mortality in low-to-middle income countries like those in sub-Saharan Africa. In Ethiopia, people with cancer who reach a hospital are diagnosed with advanced disease for which there is little treatment available and practically nothing to stem their unbearable disease-related pain. The Ethiopian government has made cancer treatment a health priority and is investing in new treatment centers and clinical services not previously available, such as radiation oncology.

image of human papilloma virus

Immune Response Induced by Vaccination May Lower Risk of New HPV Infections and Associated HPV-Related Cancers in Post-Transplant Women

Pages